Sensyne Health plc (SSYNF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sensyne Health plc (SSYNF) trades at $0.00. Sensyne Health plc is a healthcare technology company focused on developing software products that connect healthcare professionals with patients. Market cap: $33,293, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for SSYNF: SSYNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SSYNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SSYNF: 1/1 perspectives are bearish.
Sensyne Health plc (SSYNF) Healthcare & Pipeline Overview
Sensyne Health plc develops healthcare technology solutions, connecting professionals and patients via software. Its product suite includes tools for remote patient monitoring, diagnostic analysis, and chronic disease management, primarily serving the UK and US markets. The company collaborates with pharmaceutical firms and NHS Trusts to advance its AI-driven healthcare offerings.
What Is the Investment Thesis for SSYNF?
Sensyne Health operates in the high-growth digital health market, offering remote patient monitoring and AI-driven diagnostic solutions. The company's strategic collaborations with major pharmaceutical firms like Bayer and Roche, along with NHS Trusts, provide access to valuable data and clinical expertise. However, the company's OTC listing and lack of recent financial data present significant risks. The success of Sensyne Health hinges on its ability to commercialize its product pipeline and secure sustainable revenue streams. Investors should carefully consider the speculative nature of this investment, given the limited information available and the inherent challenges of the OTC market.
Based on FMP financials and quantitative analysis
SSYNF Key Highlights
- Sensyne Health develops software products connecting healthcare professionals with patients in the UK and US.
- The company's product suite includes solutions for remote patient monitoring of conditions like diabetes, COPD, and heart failure.
- Sensyne Health has strategic research alliances with pharmaceutical giants like Bayer and Roche.
- The company collaborates with NHS Trusts to deploy and validate its digital health solutions.
- Sensyne Health's technology leverages AI and machine learning to improve patient outcomes and healthcare delivery.
Who Are SSYNF's Competitors?
SSYNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CARL CARLSMED, INC. | $11.43 | -1.68% | $310.59M | 70 |
| HNGE Hinge Health, Inc. | $65.34 | +0.91% | 6B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.05 | +7.08% | $21.00M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| CSLT Castlight Health, Inc. | $2.05 | +0.00% | 54 | |
| RCM R1 RCM Inc. | $14.31 | +0.00% | $6.04B | 54 |
| BFRG Bullfrog AI Holdings, Inc. Common Stock | $0.63 | -7.29% | $6.66M | 54 |
| CERN Cerner Corporation | $94.92 | +0.00% | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SSYNF's Key Strengths?
- Proprietary AI algorithms and data analytics capabilities
- Strategic partnerships with pharmaceutical companies and NHS Trusts
- Established presence in the UK and US markets
- Comprehensive product portfolio of digital health solutions
What Are SSYNF's Weaknesses?
- OTC listing and limited financial information
- Dependence on strategic partnerships for revenue generation
- Intense competition in the digital health market
- Regulatory and data privacy risks
What Could Drive SSYNF Stock Higher?
- Expansion of remote patient monitoring solutions into new disease areas.
- Commercialization of AI-powered diagnostic tools and integration into clinical workflows.
- Potential new partnerships with pharmaceutical companies and healthcare providers.
- Geographic expansion into the United States market.
- Development of personalized medicine solutions tailored to individual patient needs.
What Are the Key Risks for SSYNF?
- Regulatory changes and data privacy concerns impacting the digital health market.
- Cybersecurity risks and data breaches compromising patient data.
- Intense competition from established players and emerging startups in the digital health space.
- Economic downturn and reduced healthcare spending affecting demand for digital health solutions.
- OTC listing and limited financial information increasing investment risk.
What Are the Growth Opportunities for SSYNF?
- Expansion of Remote Patient Monitoring Solutions: Sensyne Health can capitalize on the growing demand for remote patient monitoring by expanding its product offerings and targeting new disease areas. The global remote patient monitoring market is projected to reach $31.3 billion by 2027, driven by the increasing prevalence of chronic diseases and the need for cost-effective healthcare delivery. By leveraging its existing technology platform and partnerships with NHS Trusts, Sensyne Health can capture a significant share of this market.
- Strategic Partnerships with Pharmaceutical Companies: Sensyne Health's collaborations with pharmaceutical companies like Bayer and Roche provide access to valuable data and clinical expertise, which can be used to develop new AI-driven diagnostic and therapeutic solutions. These partnerships also offer opportunities for revenue generation through licensing agreements and joint development projects. The pharmaceutical industry is increasingly investing in digital health technologies to improve drug development and patient outcomes, creating a favorable environment for Sensyne Health's growth.
- Commercialization of AI-Powered Diagnostic Tools: Sensyne Health's AI algorithms, such as Sense, SYNE-COV, and SYNE-OPS, have the potential to transform diagnostic and treatment pathways. By commercializing these tools and integrating them into clinical workflows, Sensyne Health can generate significant revenue and improve patient outcomes. The market for AI in healthcare is projected to reach $34 billion by 2025, driven by the increasing availability of data and the advancements in machine learning technologies.
- Geographic Expansion into the United States: Sensyne Health has a presence in both the United Kingdom and the United States, but there is significant opportunity to expand its operations in the US market. The US healthcare system is characterized by high costs and inefficiencies, creating a strong demand for digital health solutions that can improve patient outcomes and reduce costs. By establishing strategic partnerships with US healthcare providers and payers, Sensyne Health can gain access to a large and growing market.
- Development of Personalized Medicine Solutions: Sensyne Health can leverage its AI capabilities and access to patient data to develop personalized medicine solutions that are tailored to individual patient needs. This approach has the potential to improve treatment outcomes and reduce healthcare costs. The personalized medicine market is projected to reach $2.4 billion by 2028, driven by the increasing availability of genomic data and the advancements in precision medicine technologies. By focusing on personalized medicine, Sensyne Health can differentiate itself from competitors and create a sustainable competitive advantage.
What Opportunities Does SSYNF Have?
- Expansion of remote patient monitoring solutions
- Commercialization of AI-powered diagnostic tools
- Geographic expansion into new markets
- Development of personalized medicine solutions
What Threats Does SSYNF Face?
- Regulatory changes and data privacy concerns
- Cybersecurity risks and data breaches
- Competition from established players and emerging startups
- Economic downturn and reduced healthcare spending
What Are SSYNF's Competitive Advantages?
- Proprietary AI algorithms and data analytics capabilities.
- Strategic partnerships with pharmaceutical companies and NHS Trusts.
- First-mover advantage in the remote patient monitoring market.
- Strong brand reputation and established relationships with key stakeholders.
What Does SSYNF Do?
Sensyne Health plc, established in 2018 and headquartered in Oxford, UK, is a healthcare technology company focused on developing software products that bridge the gap between healthcare professionals and patients. The company's core mission is to leverage technology to improve patient outcomes and streamline healthcare delivery. Sensyne Health's product portfolio includes a range of digital health solutions, such as CVm-Health for COVID-19 self-monitoring, DBm-Health for diabetes management, GDm-Health for gestational diabetes management, and BPm-Health for blood pressure monitoring during pregnancy. These products enable remote patient monitoring and facilitate data-driven decision-making for healthcare providers. In addition to remote monitoring tools, Sensyne Health offers MagnifEye for diagnostic test analysis, SEND for vital-signs observation charting, EDGE for chronic obstructive pulmonary disease (COPD) monitoring, CleanSpace for air pollution exposure monitoring, and Support-HF for heart failure monitoring. The company also develops AI-powered algorithms like Sense, SYNE-COV for COVID-19 patient outcome prediction, and SYNE-OPS for real-time patient management. Sensyne Health collaborates with pharmaceutical companies like Bayer, Roche, Alexion, and Bristol Myers Squibb, as well as NHS Trusts, to advance its research and development efforts and expand its market reach.
What Products and Services Does SSYNF Offer?
- Develops software products connecting healthcare professionals with patients.
- Offers remote patient monitoring solutions for chronic diseases like diabetes, COPD, and heart failure.
- Provides AI-powered diagnostic tools for analyzing medical data and improving treatment decisions.
- Collaborates with pharmaceutical companies to develop new digital health solutions.
- Partners with NHS Trusts to deploy and validate its technologies in real-world clinical settings.
- Focuses on leveraging data and AI to improve patient outcomes and healthcare delivery.
How Does SSYNF Make Money?
- Software-as-a-Service (SaaS) model, charging subscription fees for access to its digital health solutions.
- Licensing agreements with pharmaceutical companies for the use of its AI algorithms and data analytics capabilities.
- Joint development projects with pharmaceutical companies and healthcare providers to create new digital health solutions.
- Data analytics services, providing insights and recommendations based on patient data.
What Industry Does SSYNF Operate In?
The healthcare information services industry is experiencing rapid growth, driven by increasing adoption of digital health technologies and the need for remote patient monitoring solutions. The market is competitive, with established players and emerging startups vying for market share. Sensyne Health operates in this dynamic landscape, focusing on AI-driven solutions and strategic collaborations to differentiate itself. The industry is characterized by stringent regulatory requirements, data privacy concerns, and the need for interoperability between different systems. The global digital health market is projected to reach hundreds of billions of dollars in the coming years, presenting significant opportunities for companies like Sensyne Health.
Who Are SSYNF's Key Customers?
- Healthcare professionals, including doctors, nurses, and other clinicians.
- Patients with chronic diseases, such as diabetes, COPD, and heart failure.
- Pharmaceutical companies seeking to improve drug development and patient outcomes.
- NHS Trusts and other healthcare providers looking to improve healthcare delivery and reduce costs.
SSYNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
SSYNF Latest News
No recent news available for SSYNF.
SSYNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SSYNF.
Price Targets
Wall Street price target analysis for SSYNF.
SSYNF MoonshotScore
What does this score mean?
The MoonshotScore rates SSYNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Alexander Charles Wallace Snow
CEO
Alexander Charles Wallace Snow serves as the CEO of Sensyne Health plc. Information regarding his detailed career history, education, and previous roles is not available in the provided context. Therefore, a comprehensive background profile cannot be generated at this time. Further research would be required to provide a complete overview of his professional experience and qualifications.
Track Record: Due to the limited information available, a detailed track record of Alexander Charles Wallace Snow's achievements and strategic decisions at Sensyne Health plc cannot be provided. His tenure and specific contributions to the company's milestones remain unknown based on the provided data.
SSYNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sensyne Health plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may be subject to limited regulatory oversight and may not be required to provide regular financial reports. This lack of transparency can increase the risk for investors, as it may be difficult to assess the company's financial health and prospects. Trading on the OTC Other tier is generally considered more speculative than trading on major exchanges like the NYSE or NASDAQ, due to the higher risk of fraud and manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and regulatory oversight
- Low trading volume and liquidity
- Potential for price manipulation and fraud
- Higher risk of delisting or going out of business
- Difficulty in obtaining accurate and reliable information about the company
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Research the company's history and any past legal or regulatory issues.
- Strategic research alliances with Bayer and Roche.
- Collaboration agreement with Alexion.
- Research collaboration agreement with Bristol Myers Squibb.
- Research agreement with University of Oxford.
- Strategic research agreement with multiple NHS Trusts.
What Investors Ask About Sensyne Health plc (SSYNF) — Healthcare
What does Sensyne Health plc do?
Sensyne Health plc is a healthcare technology company that develops software products to connect healthcare professionals with patients, primarily in the United Kingdom and the United States. Their offerings include a range of digital health solutions for remote patient monitoring, diagnostic analysis, and chronic disease management. The company leverages AI and machine learning to improve patient outcomes and streamline healthcare delivery, collaborating with pharmaceutical companies and NHS Trusts to advance its research and development efforts.
What are the main risks for SSYNF?
The main risks for Sensyne Health plc include the limited financial disclosure and regulatory oversight associated with its OTC listing, which increases the potential for price manipulation and fraud. Additionally, the company faces intense competition in the digital health market, as well as regulatory and data privacy risks. Cybersecurity threats and potential economic downturns could also negatively impact the company's performance. Investors should carefully consider these risks before investing in SSYNF.
What are the key factors to evaluate for SSYNF?
Evaluate SSYNF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does SSYNF data refresh on this page?
SSYNF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SSYNF's recent stock price performance?
Sensyne Health plc (SSYNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AI algorithms and data analytics capabilities. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SSYNF overvalued or undervalued right now?
Valuing Sensyne Health plc (SSYNF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SSYNF?
Before investing in Sensyne Health plc (SSYNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SSYNF to a portfolio?
Key strength of Sensyne Health plc (SSYNF): Proprietary AI algorithms and data analytics capabilities. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Sensyne Health plc due to its OTC listing and lack of recent financial data.
- AI analysis pending for SSYNF, which may provide additional insights in the future.